Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Non-Small-Cell Lung × daratumumab × Clear all

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 85 Neoplasms, Plasma Cell 9 Recurrence 8 Immunoglobulin Light-chain Amyloidosis 6 Smoldering Multiple Myeloma 3 Neoplasms 3 Waldenstrom Macroglobulinemia 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Plasmacytoma 2 Neoplasm, Residual 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Renal Insufficiency 1 Prostatic Neoplasms 1 Paraproteinemias 1 Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1 Myelodysplastic Syndromes 1 Microsatellite Unstable Colorectal Cancer 1 Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 Hypergammaglobulinemia 1 Disease 1 Chromosome 17 deletion 1 Carcinoma, Non-Small-Cell Lung 1 Amyloidosis 1

Interventions

Carboplatin 323 Pemetrexed 249 Cisplatin 206 Paclitaxel 189 Docetaxel 185 Gemcitabine 143 Erlotinib Hydrochloride 130 Bevacizumab 124 pembrolizumab 115 Radiotherapy 100 Nivolumab 78 durvalumab 76 osimertinib 70 Drug Therapy 70 atezolizumab 51 Vinorelbine 49 Gefitinib 48 Radiosurgery 42 130-nm albumin-bound paclitaxel 34 Taxes 32 Cetuximab 32 Magnetic Resonance Spectroscopy 31 Surgical Procedures, Operative 30 Ipilimumab 30 Albumin-Bound Paclitaxel 28 Etoposide 26 tislelizumab 25 icotinib 25 anlotinib 25 Specimen Handling 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06015724 2025-07-28

DARANIVOVAX

Georgetown University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡